
Longevity InTime BioTech provides real-time monitoring and early-stage disease prediction to help individuals manage longevity-related risks. The company combines AI and Big Data models with continuous biodata collection from wearables, manual inputs, lab tests and its Bio Container to measure 400+ biomarkers. It also develops causal AI clinical-trial simulation tools and ML models trained on decades of structured clinical data to predict disease trajectories and inform prevention. The product is delivered as consumer-facing apps and integrated hardware–software kits for personal longevity monitoring.

Longevity InTime BioTech provides real-time monitoring and early-stage disease prediction to help individuals manage longevity-related risks. The company combines AI and Big Data models with continuous biodata collection from wearables, manual inputs, lab tests and its Bio Container to measure 400+ biomarkers. It also develops causal AI clinical-trial simulation tools and ML models trained on decades of structured clinical data to predict disease trajectories and inform prevention. The product is delivered as consumer-facing apps and integrated hardware–software kits for personal longevity monitoring.
Founded: 2018
Headcount (approx): 18
Product: Hardware+software platform for continuous biodata collection and AI-based longevity/disease prediction
Tech focus: AI / ML, causal AI, wearables, diagnostic kits
Funding (reported): Pre-seed; total reported $2,400,000 (USD)
Predictive, preventive, personalized healthcare and longevity monitoring
2018
Biotechnology
Reported Pre-Seed investment tied to founder Oleg Teterin; amount obfuscated in source
ALTS Accelerator reported as an investor in a Pre-Seed round; amount obfuscated in source
“ALTS Accelerator; Oleg Teterin; Google Cloud”